Introduction {#s1}
============

Nuclear RNAi is an evolutionarily conserved pathway in which small RNAs mediate transcriptional silencing and heterochromatin formation ([@bib50]; [@bib44]; [@bib34]; [@bib36]; [@bib27]). Nuclear RNAi plays an important role in genome stability and germline development. It is a highly tractable system for the study of RNA-mediated chromatin regulation and epigenetic inheritance.

*C. elegans* provides a number of unique advantages for the study of nuclear RNAi ([@bib53]). Genetic screens have identified numerous protein factors involved in this pathway. In the *C. elegans* germline, nuclear RNAi relies on the Argonaute protein HRDE-1 ([@bib3]; [@bib5]; [@bib40]). In current models, HRDE-1 binds secondary siRNAs and recruits nuclear RNAi factors, including chromatin modifying enzymes and remodeling factors, to genomic sites of RNAi. We and others have characterized over 150 genomic loci in *C. elegans* that are de-silenced and/or lose repressive chromatin modifications in nuclear RNAi-deficient mutants, the so-called 'endogenous targets' ([@bib30]; [@bib28]). In addition, nuclear RNAi-mediated silencing can be experimentally triggered at actively transcribed genes by exogenous dsRNA administration or piRNA ('exogenous targets') ([@bib1]; [@bib49]; [@bib14]; [@bib3]; [@bib13]; [@bib40]). Silencing at the exogenous targets can persist for multiple generations. Germline nuclear RNAi-deficient mutants in *C. elegans* exhibit several phenotypes, including progressive sterility under heat stress (Mrt phenotype) and large-scale de-silencing and chromatin decompaction at the endogenous targets ([@bib14]; [@bib3]; [@bib5]; [@bib40]; [@bib52]; [@bib9]).

There are two known nuclear RNAi-induced histone modifications in *C. elegans*: trimethylation at lysine 27 and lysine 9 of histone H3 (H3K27me3 and H3K9me3). The best studied nuclear RNAi-induced histone modification is H3K9me3, however the function of this histone modification in nuclear RNAi remains unknown ([@bib6]; [@bib13]; [@bib26]; [@bib17]). Prior models assumed that the heterochromatin mark was required for transcriptional silencing in nuclear RNAi, but surprisingly, H3K9me3 is not essential for silencing maintenance if HRDE-1 is present ([@bib17]; [@bib28]; [@bib54]; [@bib21]). By uncovering the histone methyltransferases (HMTs) responsible for each histone modification, we can better understand their function in nuclear RNAi. Two HMTs, MET-2 and SET-25, are suggested to function sequentially for H3K9 methylation ([@bib47]). In embryos, MET-2 and SET-25 appear to be the sole contributors of H3K9 methylation ([@bib47]; [@bib12]). However, in adults, nuclear RNAi-mediated H3K9me3 is dependent on a third additional HMT, SET-32 ([@bib26]; [@bib17]; [@bib45]). While MET-2, SET-25 and SET-32 are all required for the formation of H3K9me3, they are not functionally equivalent. MET-2, but not SET-25, is required for DNA replication stress survival ([@bib32]; [@bib55]). SET-25 and SET-32, but not MET-2, are required for the silencing of a piRNA-targeted reporter gene ([@bib3]). In addition, while MET-2, SET-25, and SET-32 were all dispensable for silencing maintenance in nuclear RNAi, SET-32 and, to a lesser extent, SET-25 are required for silencing establishment ([@bib18]; [@bib54]). Given SET-32's unique role in nuclear RNAi, we hypothesized that its biochemical activity may differ from MET-2 and SET-25.

The chromatin landscape in *C. elegans* is dynamically regulated during both somatic and germline development ([@bib37]; [@bib43]). From the embryonic stage to adulthood, the two most prominently methylated lysines of histone H3 are H3K27 and H3K23, while H3K9me is proportionally much lower ([@bib48]; [@bib43]). H3K23me has been suggested as a heterochromatin mark in *C. elegans* ([@bib48]; [@bib43]) and *Tetrahymena* ([@bib33]) and is involved in DNA damage control ([@bib33]). In comparison to the two classical heterochromatin marks, H3K9me3 and H3K27me3, H3K23me is poorly studied. Almost all histone lysine methylation is catalyzed by SET-domain containing histone methyltransferases ([@bib7]; [@bib35]; [@bib15]). Although different HMTs share core catalytic motifs in the SET domain, they can target different lysine residues with high specificity ([@bib7]). In *Tetrahymena,* the SET-domain containing enzyme, EZL3, is required for H3K23me3 *in vivo* ([@bib33]). In *C. elegans*, loss of SET-32 causes reduced levels of H3K23me1 and H3K23me2 (H3K23me3 was not tested) ([@bib54]). No H3K23 HMT has been biochemically validated at the time of this manuscript publication.

In this paper, we determined that SET-32 is an H3K23 methyltransferase *in vitro*. We show that H3K23me3 can be induced by exogenous dsRNA and persists for four generations after the dsRNA exposure has been stopped. H3K23me3 is broadly enriched in *C. elegans* heterochromatic regions, including the endogenous targets of nuclear RNAi. In addition, H3K23me3 at nuclear RNAi targets is dependent on HRDE-1 and SET-32, and, to a lesser extent, MET-2 and SET-25.

Results {#s2}
=======

SET-32 methylates lysine 23 of histone H3 *in vitro* {#s2-1}
----------------------------------------------------

To determine the enzymatic activity of SET-32, we performed histone methyltransferase (HMT) assays using recombinant GST-SET-32 and \[3H\]-labeled S-adenosylmethionine (SAM) ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We first tested SET-32's ability to methylate each of the four core histone proteins, and found that GST-SET-32 methylated free and nucleosomal H3, but not H2A, H2B, or H4 ([Figure 1A](#fig1){ref-type="fig"}). There are four conserved catalytic motifs in the SET-domain family proteins, all of which are found in SET-32 ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}; [@bib7]). The highly conserved tyrosine residue at position 448 in motif IV is predicted to be one of the catalytic residues of SET-32. In order to determine if this residue is required for SET-32's HMT function, we mutated this tyrosine to phenylalanine (Y448F). The Y448F mutation abolished the HMT activity of GST-SET-32 on H3 ([Figure 1B](#fig1){ref-type="fig"}).

![SET-32 methylates H3K23 *in vitro*.\
(**A**) Detecting the HMT activity of GST-SET-32 by \[3H\]-labeling and fluorography. Individual core histone proteins and *in vitro* assembled mononucleosome made of 601 DNA and recombinant *C. elegans* H2A, H2B, and H3.1, and *Xenopus* H4. *Xenopus* H4 was used because *C. elegans* H4 expression was not successful and there is only one amino acid difference between the two. GST-Clr4 was used as a positive control. (**B**) Fluorography of GST-SET-32 (WT and Y448) HMT assay using histone H3.1. (**C**) Top panel: fluorography of GST-SET-32 HMT assay using WT H3.1 and eight lysine mutants of H3.1. An empty lane was added between the WT H3 and H3K4L for HMT assay to avoid contamination between the WT and H3K4L lanes. Bottom panel: Coomassie staining of WT and mutant H3.1. (**D**) Mass spectrometry analysis of GST-SET-32-treated H3.1 versus untreated H3.1. The percentages of H3K23-containing fragments with H3K23me0, 1, 2, and 3 are indicated above bars.](elife-54309-fig1){#fig1}

We next investigated the target lysine of SET-32. The free N-terminal tail domain of H3 contains eight lysine residues available for methylation. To determine whether any of these lysines is required for GST-SET-32's HMT activity, we generated eight mutant H3 proteins. In each mutant, we substituted one of the eight lysines to either leucine or threonine ([Figure 1C](#fig1){ref-type="fig"}). GST-SET-32 was able to methylate every mutant H3, except for H3K23L ([Figure 1C](#fig1){ref-type="fig"}), suggesting that the lysine 23 is SET-32's target. We then performed mass spectrometry on GST-SET-32-treated H3, and detected mono, di, and tri-methylation at the K23 position ([Figure 1D](#fig1){ref-type="fig"}). The untreated control H3 had no H3K23 methylation. We did not detect methylation at any of the other lysine residues of H3. These results agree with published histone mass spectrometry analysis of *set-32* mutant animals, which exhibited reduced H3K23me compared to wild-type animals ([@bib54]). Taken together, our data indicate that SET-32 methylates H3K23 *in vitro*.

Nuclear RNAi triggers transgenerational H3K23me3 at germline genes {#s2-2}
------------------------------------------------------------------

Since SET-32 is a nuclear RNAi factor, we hypothesized that H3K23me would be induced by nuclear RNAi. Nuclear RNAi can be triggered by both exogenous dsRNA and mediated by siRNAs at the endogenous targets. We first tested whether H3K23me3 could be induced exogenously, as follows. We chose a well-characterized germline-specific gene, *oma-1*, as the target gene. To induce RNAi in *C. elegans,* we fed worms with *E. coli* expressing *oma-1* dsRNA. Wild type animals were fed with *oma-1* dsRNA, control dsRNA (GFP), or no dsRNA for 3--4 generations, and the synchronized young adult animals were then collected for ChIP-seq. All antibodies used in this study were validated using western blot and/or immunofluorescence analysis ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). In WT animals, *oma-1* dsRNA feeding triggered no detectable change in H3K23me1, a modest increase in H3K23me2, and a dramatic increase in H3K23me3 ([Figure 2A](#fig2){ref-type="fig"}). The peak of H3K23me3 corresponds to the trigger region of the *oma-1* dsRNA, and spreads approximately 0.5 kb upstream and 1 kb downstream of the *oma-1* gene boundaries. The GFP dsRNA and no dsRNA controls did not show any H3K23 methylation at *oma-1*. In order to compare H3K23me3 with a previously described dsRNA-induced histone mark, we performed side-by-side analysis of H3K23me3 and H3K9me3 and observed closely overlapping profiles ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). To verify that H3K23me3 can be induced at other genes, we fed worms with *smg-1* dsRNA and confirmed that H3K23me3 was enriched at the target chromatin in response to *smg-1* dsRNA, with a profile similar to H3K9me3 ([Figure 2B](#fig2){ref-type="fig"}).

![dsRNA triggers transgenerational H3K23me3 at the RNAi target gene.\
(**A**) H3K23 methylation levels are plotted as a function of position along the *oma-1* locus. The top panel shows input DNA for the three ChIP experiments: H3K23me1 (second panel), H3K23me2 (third panel), H3K23me3 (bottom panel); *pink: oma-1* dsRNA, *green:* GFP dsRNA, *black:* no dsRNA feed. (**B**) H3K23me3 and H3K9me3 levels are plotted as a function of position along the *smg-1* locus after *smg-1* dsRNA feeding. Yellow block highlights dsRNA trigger region. All signals are normalized to sequencing depth. (**C-D**) *oma-1* heritable RNAi assay. H3K23me3 (*left*) compared with H3K9me3 (*right*), at *oma-1* locus with *oma-1* dsRNA feeding at the F0 generation (top panel) and no dsRNA feeding in subsequent generations, F1-F4. Yellow block highlights dsRNA trigger region, orange dashed lines indicate the boundaries of *oma-1*. The data in this figure is representative of 1 replicate (H3K23me1, H3K23me2, heritable oma-1, smg-1), and three replicates for H3K23me3 and H3K9me3 *oma-1*.](elife-54309-fig2){#fig2}

In order to examine the transgenerational dynamics of dsRNA-induced H3K23me3, we performed a heritable RNAi experiment of *oma-1*. WT animals were fed *oma-1* dsRNA for three generations and subsequently moved to dsRNA-free plates and collected for four generations. Similar to H3K9me3, H3K23me3 at *oma-1* persisted for four generations after the RNA-feeding had been stopped ([Figure 2C and D](#fig2){ref-type="fig"}). These results indicate that RNAi-mediated H3K23me3 is a transgenerational epigenetic effect in *C. elegans*.

H3K23me3 is a heterochromatic mark in *C. elegans* {#s2-3}
--------------------------------------------------

In order to further characterize H3K23me in *C. elegans,* we conducted ChIP-seq in WT animals and performed whole-genome analysis. The genomic distribution of H3K23me3 was highly similar to the genomic distribution of H3K9me3 ([Figure 3A--B](#fig3){ref-type="fig"} and [Figure 3---figure supplements 1](#fig3s1){ref-type="fig"} and [2](#fig3s2){ref-type="fig"}). We observed H3K23me3 enrichment at constitutive heterochromatin domains: the left and right arms of the five autosomes and the left tip of the X chromosome. Like H3K9me3, we observed the highest peaks of H3K23me3 at the meiotic paring centers ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). H3K23me2 and H3K23me1 seem to have a relative uniform distribution in the genome ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). In order to quantify our coverage plots, we used boxplot analysis to compare the ChIP-seq signal at the arms of each chromosome compared with the middle ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). As expected, H3K9me3 shows statistically significant enrichment at the arms compared to the middle of each chromosome. H3K23me3 also displays enrichment at the arms, however, to a lesser extent. In this analysis, we found that while there were statistically significant differences between the arms and the middle in H3K23me2 and H3K23me1, the magnitude of difference is virtually indiscernible making it highly likely that these differences have little biological significance.

![H3K23 methylation profiles at endogenous germline nuclear RNAi targets in WT.\
(**A**) Relative enrichment (y axis) of H3K23me1, H3K23me2, H3K23me3, H3K9me3 ChIP (top to bottom) to input for chromosome V (x axis). Black bar indicates approximate location of meiotic paring center. (**B**) Scatter plot of H3K23me3 ChIP/input (y axis) vs H3K9me3 ChIP/input (x axis) for the whole genome, in which each point represents a 1kb segment of the genome. Averaged values from two replicates were used. (**C**) H3K23me1, H3K23me2, H3K23me3, and H3K9me3 enrichment (y axis) at an endogenous germline nuclear RNAi target, *Cer3* LTR retrotransposon (x axis). *Grey* is the input signal. (**D**) Scatter plot comparing the H3K23me3 whole-genome profiles (1kb windows) in *glp-1(e2141)* and WT adult animals (25°C). Curved dashed lines indicated two-fold difference (FDR≤0.05). Regions of germline nuclear RNAi-mediated heterochromatin (GRH) are highlighted in blue and regions of germline nuclear RNAi-mediated transcriptional silencing (GRTS) in pink. (**E-H**) H3K9me3 (*black*) and H3K23me3 (*pink*) coverage plots for three other endogenous targets, (E) *Cer8,* (F) an exemplary GRH locus on chromosome V:5465000-5485000, (G) *eri-6,* and (H) a control euchromatin locus, *cdc-42.* All signals are normalized to sequencing depth. The data in this figure is representative of 1 replicate (H3K23me1, H3K23me2, H3K27me3, *glp-1*), or 3 replicates (H3K23me3 & H3K9me3).](elife-54309-fig3){#fig3}

Our results are consistent with previous reports that H3K23me3 is a constitutive heterochromatin mark ([@bib33]; [@bib48]; [@bib43]). In order to further assess the correspondence of H3K23me3 and H3K9me3, we plotted whole genome coverage of both modifications on a scatter plot and observed a high correlation (Pearson coefficient = 0.8) ([Figure 3B](#fig3){ref-type="fig"}). Our data confirm previous reports that H3K23me3 is heterochromatic in distribution and correlates highly with H3K9me3.

H3K23me3 is enriched at endogenous targets of nuclear RNAi {#s2-4}
----------------------------------------------------------

We have previously described a set of endogenous targets of germline nuclear RNAi which consist mainly of LTR retrotransposons and other repetitive genomic elements. These HRDE-1*-*dependent loci are transcriptionally silenced and enriched for H3K9me3. We examined several of these loci for H3K23 methylation using ChIP-seq ([Figure 3C,E--G](#fig3){ref-type="fig"}). At the LTR retrotransposon *Cer3,* H3K23me1 signal was double that of the input, however, the signal was still relatively low ([Figure 3C](#fig3){ref-type="fig"}). We observed a stronger signal for H3K23me2 and a robust signal for H3K23me3 ([Figure 3C](#fig3){ref-type="fig"}). At the endogenous targets, H3K23me3 closely resembles the H3K9me3 signal ([Figure 3C,E--G](#fig3){ref-type="fig"}). By contrast, the actively transcribed *cdc-42* locus did not show any enrichment of either H3K9me3 or H3K23me3 ([Figure 3H](#fig3){ref-type="fig"}). These data demonstrate that H3K23me3 is enriched at endogenous nuclear RNAi targets.

As nuclear RNAi is heritable and requires germline factors, we also wished to assess the whether H3K23me3 is a germline-specific histone modification. *glp-1(e2141)* mutants are defective in germ cell proliferation at the restrictive temperature (25°C). By comparing the *glp-1* mutant and WT worms, we were able to determine that nuclear RNAi-induced H3K23me3 is indeed greatly enriched in the germline ([Figure 3D](#fig3){ref-type="fig"}). However, H3K23me3 was still present in the *glp-1* mutant animals at both nuclear RNAi targets and globally, indicating that H3K23me3 occurs in both soma and germline.

By analyzing both exogenous ([Figure 2](#fig2){ref-type="fig"}) and endogenous targets ([Figure 3](#fig3){ref-type="fig"}), we determined that H3K23me3, like H3K9me3, is a nuclear RNAi-induced heterochromatic mark.

*set-32* and *hrde-1* are required for nuclear RNAi-induced H3K23me3 {#s2-5}
--------------------------------------------------------------------

In order to elucidate the genetic requirements of nuclear RNAi-induced H3K23me3, we performed dsRNA feeding against *oma-1* in three different mutant strains, *hrde-1, set-*32 single mutant, and *met-2 set-25* double mutant, followed by H3K23me3 ChIP-seq ([Figure 4A](#fig4){ref-type="fig"}). As expected, *hrde-1* and *set-32* mutant worms showed greatly reduced H3K23me3 at the *oma-1* locus compared to WT. By contrast, *oma-1* RNAi in the double HMT mutant, *met-2 set-25,* and the WT animals induced similar, high levels of H3K23me3, indicating that SET-32 has a specific role in H3K23 methylation not shared by the other two HMTs ([Figure 4A](#fig4){ref-type="fig"}).

![*set-32* and *hrde-1* are required for nuclear RNAi-dependent H3K23me3.\
(**A--D**) H3K23 methylation levels (y axis) are plotted as a function of genomic position (x axis) in three mutant strains. Top panel: *hrde-1*, middle panel: *set-32*, bottom panel: *met-2 set-25*. The same H3K23me3 signal from WT animals (*black)* was plotted in each panel to compare with the mutant signals (*pink*). Grey: ChIP input from WT. (**A**) *oma-1* locus with exogenous dsRNA-induced nuclear RNAi. Yellow block highlights the dsRNA trigger region, orange dashed lines indicate the boundaries of *oma-1*. (**B-C**) Endogenous targets of nuclear RNAi, (**B**) an exemplary GRH locus on chromosome V:5465000--5485000, (**C**) Cer8, (**D**) *Y23H5A.7a,* a top *hrde-1-*dependent gene. (**E**) Box plot of H3K23me3 ChIP whole-genome coverage in mutant/WT comparing GRH and GRTS regions, as well as the rest of the genome. (**F**) Venn diagram of genes enriched with *hrde-1* (orange), *set-32* (blue), and *met-2 set-25* (green)-dependent H3K23me3. Dependence is measured as a twofold decrease in H3K23me3 signal in mutant compared with WT for individual annotated protein-coding genes in two replicas (p value \< 0.05). Fisher's exact test found the overlap between all pairs are statistically significant; the p values are \< 2.2×10^−16^ for *hrde-1* vs *set-32* and *set-32* vs *met-2 set-25* and 2.095 × 10^−15^ for *hrde-1* vs *met-2 set-25*. The data in this figure is representative of one replicate (*hrde-1 oma-1* RNAi), two replicates (all other genotypes in *oma-1* RNAi) or three replicates (all genotypes no RNAi).](elife-54309-fig4){#fig4}

Interestingly, the genetic requirements at endogenous targets were harder to parse. We did not observe consistent reduction in the mutants across different endogenous targets ([Figure 4B--D](#fig4){ref-type="fig"} & [Figure 4---figure supplement 1D--G](#fig4s1){ref-type="fig"}). We found that while some targets display loss of H3K23me3 in *hrde-1* and *set-32* mutants but not *met-2 set-25* ([Figure 4B](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), this was not true for all of them. At some loci, the reduction in H3K23me3 was the most apparent in either *set-32* mutants ([Figure 4C](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}) or in *hrde-1* mutants ([Figure 4D](#fig4){ref-type="fig"}). Still other targets displayed a weak reduction in all three mutations ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). These findings indicate that the regulation of H3K23me3 at nuclear RNAi targets is complex, and likely to involve other HMTs. When we examined the loss of H3K9me3 in the mutants at the same genomic loci, we do not see the same variation ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). These data indicate a complex regulation of heterochromatin marks at the endogenous targets and suggest that the genetic requirements may be contingent on local chromatin environment and other factors.

To further quantify these results, we used whole genome scatter plots ([Figure 4---figure supplement 1A--C](#fig4s1){ref-type="fig"}) and box plots ([Figure 4E](#fig4){ref-type="fig"}). We did not observe complete abolishment of H3K23me3 in the *set-32* or *hrde-1* mutant animals at the global level ([Figure 4---figure supplement 1A--C](#fig4s1){ref-type="fig"}). However, we did see a strong loss of H3K23me3 at endogenous nuclear RNAi targets in both the *hrde-1* and *set-32* mutant animals and weaker H3K23me3 reduction in the *met-2 set-25* double mutant animals ([Figure 4E](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A--C](#fig4s1){ref-type="fig"}). In published works, we have shown that H3K9me3 has a larger requirement of MET-2 and SET-25 than SET-32, further supporting the different functions of SET-32 and MET-2/SET-25 ([@bib17]; [@bib45]).

In order to better understand the contribution of the three HMTs and HRDE-1 to H3K23me3, we used Venn diagram analysis ([Figure 4F](#fig4){ref-type="fig"}). Previous studies have suggested that SET-32 is a nuclear RNAi-specific factor, we therefore expected that the regions of SET-32-dependent H3K23me3 would overlap with HRDE-1 targets. To probe this question, we identified genes with SET-32 or HRDE-1-dependent H3K23me3 profiles. The lists of the top SET-32 and HRDE-1-dependent genes are heavily populated by our previously defined endogenous targets and contain several classes of repeat elements ([Supplementary file 1](#supp1){ref-type="supplementary-material"} and [Figure 4---figure supplement 1F--G](#fig4s1){ref-type="fig"} for example coverage plots). We then performed a Venn diagram analysis and found that the majority of SET-32-dependent genes overlapped with HRDE-1-dependent genes ([Figure 4F](#fig4){ref-type="fig"}). There are over 150 SET-32-dependent H3K23me3 genes, in contrast there are only 40 MET-2 SET-25-dependent H3K23me3 genes. In comparison, there are three times as many MET-2 SET-25-dependent H3K9me3 genes as there are SET-32-dependent H3K9me3 genes ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

To further explore the targets of H3K23me3 in nuclear RNAi, we performed gene analysis on the *hrde-1*-dependent H3K23me3 genes. In this analysis, we found that while no class of genes was enriched in these targets, 61.4% of the genes were enriched for repeat DNA of varying classes ([Figure 4---figure supplement 4A](#fig4s4){ref-type="fig"}). The majority of repeats were low complexity and DNA repeats ([Figure 4---figure supplement 4C](#fig4s4){ref-type="fig"}). However, there was also an enrichment of LTRs (4.37% percent of genes containing repeats contained LTRs) ([Figure 4---figure supplement 4C](#fig4s4){ref-type="fig"}). We did the same analysis of *hrde-1*-dependent H3K9me3 genes and found no significant difference in repeat frequency or type ([Figure 4---figure supplement 4B and D](#fig4s4){ref-type="fig"}).

Discussion {#s3}
==========

*C. elegans* as a model system to study H3K23 methylation {#s3-1}
---------------------------------------------------------

H3K23 methylation was discovered in alfalfa in 1990 ([@bib51]) and has subsequently been found in yeast, *Tetrahymena, C. elegans*, mouse, rat, pig and human ([@bib51]; [@bib11]; [@bib23]; [@bib24]; [@bib57]; [@bib33]; [@bib48]; [@bib43]; [@bib46]; [@bib10]; [@bib29]; [@bib54]; [@bib22]). Despite its high degree of evolutionary conservation, H3K23me remains an understudied histone modification. H3K23 is the second most highly methylated lysine of H3 in *C. elegans* ([@bib33]). The developmental dynamics of H3K23me have been characterized, either alone or in combination with other histone modifications ([@bib33]; [@bib43]). The whole-genome distributions of H3K23me have been determined in this work and previous studies ([@bib48]; [@bib43]). In addition, this study discovered the first biochemically validated H3K23 histone methyltransferase (HMT) and demonstrated that H3K23me3 can be experimentally induced at RNAi target genes. These advances uniquely position *C. elegans* as a powerful system to explore the regulation and function of H3K23 methylation.

Nuclear RNAi induces multiple heterochromatin marks {#s3-2}
---------------------------------------------------

Previous studies identified H3K9me3 and H3K27me3 as nuclear RNAi-mediated histone modifications ([@bib13]; [@bib26]). This study adds H3K23me3 to the list. Based on these results, we propose that the revised model should include the following features. (1) Different marks at nuclear RNAi targets are deposited by different HMTs: MET-2 and SET-25 for H3K9me3, MES-2 for H3K27me3, and SET-32 and unknown other HMT(s) for H3K23me3. (2) The genetic requirement of SET-32 for H3K9me3 suggests that H3K23me3 promotes H3K9me3. (3) At some of the endogenous nuclear RNAi targets, H3K9me3 and H3K23me3 appear to be mutually dependent. (4) H3K27me3 is largely independent of H3K9me3 and H3K23me3 ([@bib17]). Future studies are needed to further delineate the relationship of these histone marks and determine the mechanisms by which the HMTs are recruited to target chromatin.

What is the function of H3K23me3 in nuclear RNAi? {#s3-3}
-------------------------------------------------

The involvement of SET-32 in both the maintenance and establishment phases of nuclear RNAi suggests that H3K23me3 functions in these phases as well ([@bib17]; [@bib45]; [@bib18]; [@bib54]). During the establishment phase of nuclear RNAi, the host organism encounters a foreign genetic element for the first time and must repress its active transcription. In the maintenance phase, a stable silencing state is passed on from parent to progeny.

### Maintenance {#s3-3-1}

SET-32 is dispensable for silencing maintenance when in the presence of wild-type HRDE-1. However, *set-32 hrde-1* double mutants show enhanced de-silencing when compared to *hrde-1* single mutants ([@bib18]). These results suggest a conditional requirement of H3K23me3 for silencing maintenance, possibly to function as a failsafe or backup silencing mechanism.

### Establishment {#s3-3-2}

Recent studies have shown that SET-32 is required for silencing establishment at both exogenous dsRNA targets and endogenous targets ([@bib18]; [@bib54]). Unlike in the maintenance phase, SET-32 is required in silencing establishment, even when HRDE-1 is intact, suggesting that H3K23me3 plays a more prominent role in the establishment phase than the maintenance phase.

### The functional relationship between H3K23me3 and H3K9me3 {#s3-3-3}

The co-occurrence of H3K9me3 and H3K23me3 could indicate that they work together to play a larger role in heterochromatin architecture. Both H3K9me3 and H3K23me3 have been shown to bind human HP1 or its orthologs *in vitro* ([@bib39]). In addition, both HP1α and H3K23me2 are enriched in the nuclear pore complex in HeLa cells (H3K23me3 was not tested) ([@bib10]). Future studies are needed to investigate whether similar molecular interactions occur in *C. elegans* and dissect the distinct functions associated with H3K23me3 and H3K9me3.

Additional H3K23 histone methyltransferases {#s3-4}
-------------------------------------------

Like H3K9me3, H3K23me3 is broadly enriched in *C. elegans* heterochromatin. Our study indicates that SET-32 primarily targets the nuclear RNAi loci for H3K23me3. H3K23me3 in other heterochromatic regions is deposited by other known H3K23 HMT(s). In addition, the unknown H3K23 HMTs are likely to deposit a small fraction of H3K23me3 in the nuclear RNAi targets. We and others observed no obvious defects in animal development or mRNA expression in *set-32* mutants ([@bib2]; [@bib17]; [@bib54]); however, given the abundance of H3K23me in worms, we think it likely that upon identification of other H3K23me HMT(s), a combinatorial mutant will show defects. Future studies are needed to identify additional H3K23 HMTs and the broader function of H3K23me.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                              Designation                                                Source or reference                                             Identifiers                        Additional\
  (species) or resource                                                                                                                                                                                    information
  ------------------------------------------ ---------------------------------------------------------- --------------------------------------------------------------- ---------------------------------- ------------------------------------
  Commercial assay or kit                    KAPA Hyper Prep Kit                                        KAPA Biosystems                                                                                    

  Commercial assay or kit                    Vivaspin columns (MWCO 30 KDa)                             GE healthcare                                                                                      

  Peptide, recombinant protein               *Xenopus* H4                                               Histone Source                                                                                     

  Strain, strain background (*C. elegans*)   WT                                                         Caenorhabditis Genetics Center                                  N2                                 

  Strain, strain background (*C. elegans*)   *set-32*                                                   PMID:[30463021](https://www.ncbi.nlm.nih.gov/pubmed/30463021)   LG I: *set-32*(red11)              

  Strain, strain background (*C. elegans*)   *hrde-1*                                                   Caenorhabditis Genetics Center                                  LG III: *hrde-1*(tm1200)           

  Strain, strain background (*C. elegans*)   *glp-1*                                                    Caenorhabditis Genetics Center                                  *glp-1*(e2141)                     

  Strain, strain background (*C. elegans*)   *met-2, set-25*                                            Caenorhabditis Genetics Center                                  *met-2*(n4256) *set-25* (ok5021)   

  Antibody                                   rabbit polyclonal anti-H3K9me3                             Abcam                                                           ab8898                             Anitbody for ChIP seq

  Antibody                                   rabbit polyclonal anti-H3K23me3                            Active Motif                                                    61500                              Anitbody for ChIP seq

  Antibody                                   rabbit polyclonal anti-H3K23me2                            Active Motif                                                    39654                              Anitbody for ChIP seq

  Antibody                                   rabbit polyclonal anti-H3K23me1                            Active Motif                                                    39388                              Anitbody for ChIP seq

  Antibody                                   mouse monoclonal anti-H3K27me3                             Active Motif                                                    39535                              Anitbody for ChIP seq

  Antibody                                   Donkey Anti-Rabbit-Alexa Fluor 488                         Jackson ImmunoResearch Laboratories                             711-545-152                        (1:300)

  Antibody                                   monoclonal Mouse-anti-tubulin                              DSHB                                                            AA4.3                              (1:250)

  Antibody                                   Cy5-conjugated donkey anti-Rabbit IgG secondary antibody   Jackson ImmunoResearch Laboratories                             711-175-152                        (1:1000)

  Antibody                                   Cy5-conjugated donkey anti-Mouse IgG secondary antibody    Jackson ImmunoResearch Laboratories                             715-175-150                        (1:1000)

  Peptide, recombinant protein               histone H3K23me3                                           Active Motif                                                    31264                              antibody validation

  Peptide, recombinant protein               histone H3K9me3                                            Active Motif                                                    31601                              antibody validation

  Peptide, recombinant protein               unmodified histone H3                                      Abcam                                                           ab2903                             antibody validation

  Peptide, recombinant protein               H3K27me3 histone peptide                                   Abcam                                                           ab1782                             antibody validation

  Plasmid                                    pGEX-6p-1-GST-SET-32-WT                                    This study                                                      pSG361                             recombinant protein expression

  Plasmid                                    pGEX-6p-1-GST-SET-32-(Y448F)                               This study                                                      pSG434                             recombinant protein expression

  Plasmid                                    pGEX-6p-1-GST-SET-25-WT                                    This study                                                      pSG355                             recombinant protein expression

  Plasmid                                    pet28a_human_H3.1_WT                                       Addgene, a gift from Joe Landry                                 42631                              recombinant protein expression

  Plasmid                                    pet28a_human_H3.1_K4L                                      This study                                                      pSG371                             recombinant protein expression

  Plasmid                                    pet28a_human_H3.1_K9L                                      This study                                                      pSG367                             recombinant protein expression

  Plasmid                                    pet28a_human_H3.1_K14T                                     This study                                                      pSG372                             recombinant protein expression

  Plasmid                                    pet28a_human_H3.1_K18L                                     This study                                                      pSG373                             recombinant protein expression

  Plasmid                                    pet28a_human_H3.1_K23L                                     This study                                                      pSG374                             recombinant protein expression

  Plasmid                                    pet28a_human_H3.1_K27L                                     This study                                                      pSG375                             recombinant protein expression

  Plasmid                                    pet28a_human_H3.1_K36L                                     This study                                                      pSG376                             recombinant protein expression

  Plasmid                                    pet28a_human_H3.1_K37L                                     This study                                                      pSG377                             recombinant protein expression

  Plasmid                                    pet28a_elegans_H2A                                         This study                                                      pSG395                             recombinant protein expression

  Plasmid                                    pet28a_elegans_H2B                                         This study                                                      pSG427                             recombinant protein expression

  Plasmid                                    pet28a_elegans_H3.1                                        This study                                                      pSG428                             recombinant protein expression

  Plasmid                                    L4440-oma-1                                                PMID:[28228846](https://www.ncbi.nlm.nih.gov/pubmed/28228846)   pSG42                              RNAi feeding plasmid against oma-1

  Plasmid                                    L4440-smg-1                                                PMID:[22231482](https://www.ncbi.nlm.nih.gov/pubmed/22231482)   pSG27                              RNAi feeding plasmid against smg-1

  Plasmid                                    L4440-GFP                                                  A gift from Andrew Fire lab                                     L4417                              RNAi feeding plasmid against GFP
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Plasmid construction and recombinant protein purification for GST-fusion proteins {#s4-1}
---------------------------------------------------------------------------------

The pGEX-6P-1-GST-SET-32-WT (pSG361) and pGEX-6P-1-GST-SET-25-WT (pSG355) were generated by inserting *set-32* and *set-25* cDNA fragments into the plasmid pGEX-6P-1 using the BamHI and NotI sites. The *set-32* cDNA fragment was amplified by RT-PCR using *C. elegans* (N2) mRNA. The codon optimized *set-25* cDNA fragment was purchased from IDT as gBlock DNA. To create the pGEX-6P-1-GST-SET-32-Y448F plasmid (pSG434), the AccI-NotI fragment of the pGEX-6P-1-GST-SET-32-WT was replaced with gBlock DNA from IDT carrying the Y448F mutation. Plasmids sequences were confirmed by Sanger sequencing. pGEX-6P-1-GST-Clr4 was a gift from the Danesh Moazed ([@bib16]).

The procedure for protein expression and purification was adapted from [@bib16]. Briefly, *E. coli* BL21-Gold (DE3) that was transformed with the expression plasmid was cultured in 2xYT at 37°C until OD600 reached 0.6--0.8, followed by incubating on ice for 30 min, and then 30 min of 18°C in shaker before IPTG induction. Recombinant protein expression was induced by 0.2 mM IPTG and continued overnight in the 18°C shaker. All samples and reagents were placed on ice or in the cold room during protein purification. Cells were collected, resuspended in a lysis buffer (150 mM NaCl, 20 mM sodium phosphate pH = 7.4, 1% Triton X-100, 1 mM DTT, and 1 mM PMSF), and lysed by Bioruptor using the high output and five 8-min sessions with 30 s on/30 s off cycle. A large fraction of the GST-SET-32 and GST-SET-25 were lost as inclusion bodies. After a clear spin, the soluble GST-tagged protein was pulled down by rotating the sample with glutathione sepharose beads for 1 hr. The beads were washed in a buffer containing 150 mM NaCl, 20 mM sodium phosphate pH = 7.4, 1 mM DTT, and 1 mM PMSF three times. Protein was eluted using a buffer containing 50 mM Tris-HCl pH = 8.0, 15 mM glutathione, 10% glycerol, 1 mM PMSF, and 1 mM DTT, dialyzed against the storage buffer (50 mM Tris-HCl pH = 8.0, 10% glycerol, 1 mM PMSF, and 1 mM DTT), and concentrated using the Vivaspin columns (MWCO 30 KDa, GE healthcare). The remaining soluble GST-SET-32 aggregates to form \>600 KDa complex as measured by size exclusion chromatography analysis ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}).

Plasmid construction and recombinant protein purification for histone H3 proteins {#s4-2}
---------------------------------------------------------------------------------

Plasmid pet28a_human_H3.1 (a gift from Joe Landry, Addgene plasmid \# 42631) was used to construct the mutant H3 expression plasmids used in this study. The H3K4L, H3K9L, H3K14T, and H3K18L mutations were introduced by replacing the NcoI-MscI fragment in pet28a_human_H3.1 with NcoI-MscI fragments containing the corresponding mutations. Similarly, the MscI-AgeI fragments were used to make the H3K23L and H3K27L mutations and the AgeI-SalI fragments were used for H3K36L and H3K37L mutations. The single-stranded oligoes or oligo duplex pairs were used to make the mutation-containing fragments. Plasmids pet28a_elegans_H2A (*his-12*, pSG395), pet28a_elegans_H2B (*his-11*, pSG396), pet28a_elegans_H3.1 (*his-9*, pSG397), and pet28a_elegans_H4 (*his-31*, pSG398) were constructed by inserting the cDNA fragments amplified using *C. elegans* mRNA by RT-PCR into the NcoI and NotI sites. The *C. elegans* H2A, H2B, H3.1, and H4 cDNA fragments were amplified by using mRNA isolated from wild type animals. Plasmids sequences were confirmed by Sanger sequencing.

Histone purification was performed using the protocol as previously described in [@bib19]. Briefly, *E. coli* BL21-Gold (DE3) that was transformed with the expression plasmid was cultured in 2xYT medium at 37°C until OD600 reached 0.6--0.8. After 1 mM IPTG was added, cells were cultured for 4 hr at 37°C. Two gams of cells were resuspended with 1 ml 10x SA buffer (400 mM sodium acetate, pH 5.2, 10 mM EDTA, 100 mM lysine), 0.5 ml 4M NaCl, 100 μl 100 mM PMSF, 100 μl HALT protease inhibitor, 3.5 μl 2-mercaptoethanol, 3.6 g urea, and diH2O to a final volume of 10 ml. Cells were lysed by Bioruptor using the high output for five 8-min sessions with 30 s on/30 s off cycle. After 20 min of spin at 41,000xg, the supernatant was filtered with 0.45 μM syringe filter and passed through the HiTrap Q 5 ml column on a FPLC machine. The flow-through was loaded onto HiTrap SP 5 ml column. The elution was done by 25 ml 0--19% buffer B and 50 ml 19--50% buffer B. Buffer A contains 40 mM sodium acetate, pH 5.2, 1 mM EDTA, 10 mM lysine, 200 mM NaCl, 6 M urea, 1 mM PMSF, 5 mM 2-mercaptoethanol. Buffer B has 1 M NaCl and is otherwise the same as buffer A. Histone containing fractions were determined by SDS-PAGE/coomassie analysis. The expression of *C. elegans* H2A, H2B, and H3 was successfully but H4 was not ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). *Xenopus* H4 (Histone Source), which is identical to *C. elegans* H4 except at position 74 (threonine in *Xenopus* and cysteine for *C. elegans*), was used for nucleosome assembly.

Nucleosome assembly {#s4-3}
-------------------

Nucleosome was assembled as previously described ([@bib25]; [@bib19]; [@bib8]). Briefly, *C. elegans* H2A (12 μM), H2B (12 μM), H3 (10 μM), and *Xenopus* H4 (10 μM) (Histone Source) proteins were mixed in a 250 μl final volume containing 7 M guanidinium HCl, 20 mM Tris-HCl, pH 7.5, 10 mM DTT. Guanidinium HCl was added directly to the mixture, which was then rotated at room temperature for 30--60 min to dissolve guanidinium and spun to clear the mixture. The supernatant was dialyzed against 1L refolding buffer (2M NaCl, 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 5 mM 2-mercaptoethanol) three times (2 hr overnight, and 2 hr in the cold room). After a clear spin, the sample was fractionated by size exclusion chromatography (Superdex 200 10/300 GL) in the refolding buffer. The histone octamer fractions were identified by SDS-PAGE/coomassie analysis ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). 12 μg 601 DNA (Histone Source) in 2 M NaCl was mixed with 12 μg histone octamer in the refolding buffer and then dialyzed against a series of buffers with 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, and reducing amounts of NaCl (1 M, 0.8 M, 0.6 M, and 0.05 M), 2 hr for each dialysis. The reconstituted nucleosome was heated at 55°C for 20 min and then cooled to room temperature for 10 min for most thermal stable nucleosome positioning. The nucleosome was concentrated and used for the HMT assay.

HMT assay {#s4-4}
---------

The HMT assay was performed as described in [@bib16]. Briefly, the \[3H\]-based HMT assay was carried out in a 10 µl reaction mix containing 2 µM histone or nucleosome, 5.6 µM \[3H\]- S-adenosyl methionine (SAM), 0.3--1 µM enzyme, and 1x HMT buffer (50 mM Tris-HCl, pH 8.0, 20 mM KCl, 10 mM MgCl~2~, 0.02% Triton X-100, 1 mM DTT, 5% glycerol, and 1 mM PMSF). The reaction mix was incubated at 20°C for 2 hr, and then loaded onto 17% SDS-PAGE. After electrophoresis, proteins were transferred to PVDF membrane, which was then soaked with autoradiography enhancer (EN3HANCE, PerkinElmer) and then air dried. Fluorography signal was detected by X-ray film. For the histone mass spectrometry analysis, 150 µl reaction mix containing approximately 0.3 µM GST-SET-32, 2.5 µM H3, and 213 µM SAM and 1 x HMT buffer without Triton X-100 was used.

Mass spectrometry {#s4-5}
-----------------

Histone peptides were obtained as previously described ([@bib42]). Briefly, histone pellets were resuspended in 20 μL of 50 mM NH~4~HCO~3~ (pH 8.0) plus 5 µl of acetonitrile. Derivatization was performed by adding 5 µl of propionic anhydride rapidly followed by 16 µl of ammonium hydroxide and incubated for 20 min at room temperature. The reaction was performed twice to ensure complete derivatization of unmodified and monomethylated lysine residues. Samples were then dried, resuspended in 20 μL of 50 mM NH~4~HCO~3~ and digested with trypsin (Promega) (enzyme:sample ratio = 1:20, 2 hr, room temperature). The derivatization reaction was then performed again twice to derivatize peptide N-termini. Samples were then desalted by using in-house packed stage-tips and dried using a SpeedVac centrifuge.

Dried samples were resuspended in 0.1% trifluoroacetic acid (TFA) and injected onto a 75 µm ID x 25 cm Reprosil-Pur C18-AQ (3 µm; Dr. Maisch GmbH, Germany) nano-column packed in-house using a Dionex RSLC nanoHPLC (Thermo Scientific, San Jose, CA, USA). The nanoLC pumped a flow-rate of 300 nL/min with a programmed gradient from 5% to 28% solvent B (A = 0.1% formic acid; B = 80% acetonitrile, 0.1% formic acid) over 45 min, followed by a gradient from 28% to 80% solvent B in 5 min and 10 min isocratic at 80% B. The instrument was coupled online with a Q-Exactive HF (Thermo Scientific, Bremen, Germany) mass spectrometer acquiring data in a data-independent acquisition (DIA) mode as previously optimized ([@bib41]). Briefly, DIA consisted on a full scan MS (*m/z* 300--1100) followed by 16 MS/MS with windows of 50 *m/z* using HCD fragmentation and detected all in the orbitrap analyzer.

DIA data were searched using EpiProfile 2.0 and validated manually ([@bib56]). The histone H3 peptide KQLATKAAR (aa 18--26) was considered in all possible modified forms (unmodified, me1/2/3). The relative abundance of each form was calculated using the total area under the extracted ion chromatograms of all peptides in all the (un)modified forms and considered that as 100%. To confirm the position of the methylation, we extracted the chromatographic profile of the MS/MS fragment ions and verified that no unique fragment ions belonging to the K18me1/2/3 possible peptide isoforms had detectable intensity.

*C. elegans* strains {#s4-6}
--------------------

*C. elegans* strain N2 was used as the standard WT strain. Alleles used in this study were: LG I: *set-32*(red11), LG III: *hrde-1*(tm1200), *glp-1*(e2141), *set-25*(n5021), *set-32*(ok1457), *met-2*(n4256) *set-25* (ok5021). *C. elegans* were cultured on NMG agar plates as previously described ([@bib4]) in a temperature-controlled incubator.

Preparation of worm grinds {#s4-7}
--------------------------

Synchronized young adult worms were first washed off the plates with M9 buffer. *E. coli* OP50 bacteria washed off together with the worms were separated and removed by loading the worms to 10% sucrose cushion and centrifuging for 1 min at 600 g in a clinical centrifuge. Worms were then pulverized by grinding in liquid nitrogen with a pre-chilled mortar and pestle and were stored at −80°C.

dsRNA feeding {#s4-8}
-------------

Worms were grown on NGM plates with the following food sources: OP50 *E. coli* (no RNAi), *oma-1 E. coli* (plasmid SG42), GFP *E. coli* (plasmid SG221), *smg-1 E. coli* (plasmid SG27). Worms were synchronized by bleaching, subsequent starvation and released at the L1 stage onto described plates. Each assay in this study used grinds of \~5000 worms for each condition. For RNAi experiments, worms were grown for three to four generations on RNAi culture before grinding. For heritable RNAi experiments, we used the protocol described in [@bib13]. Briefly, worms were raised on oma-1 RNAi plates for three generations before synchronization and release onto OP50 *E. coli* plates without dsRNA feed. Worms were collected at P0, F1, F2, F3, F4 generations for grinding.

ChIP-seq library construction {#s4-9}
-----------------------------

Worm grinds from approximately 5000 worms were used for each chromatin immunoprecipitation experiment according to the procedure described in [@bib30]. Anti-H3K9me3 (ab8898, Abcam) and anti-H3K23me3 (61500, Active Motif) antibodies were used for the H3K9me3 and H3K23me3 ChIP, respectively. Each ChIP experiments usually yielded 5--10 ng DNA. The entire ChIP DNA or 10 ng DNA in the case of ChIP input was used to make DNA library with the KAPA Hyper Prep Kit (KAPA Biosystems) according to the manufacturer's instruction. For each sample in a given assay, worm grinds were thawed and subsequently crosslinked and sonicated to produce fragments between 200 and 500 bp according to protocol described in [@bib31]. Samples were then used for ChIP (H3K23me1,2,3, H3K9me3, H3K27me3) or stored for library prep as input DNA. IP was performed with the following antibodies: anti-H3K9me3 (ab8898, Abcam), anti-H3K23me1 (39388, Active Motif), anti-H3K23me2 (39654, Active Motif), anti-H3K23me3 (61500, Active Motif), and anti-H3K27me3 (39535, Active Motif). For each antibody, \~0.5--1.5% of input DNA was pulled down, with DNA yields between \~5 and 25 ng. 5 ng or less of DNA was used for library preparation using KAPA Hyper Prep Kit (KAPA Biosystems) according to the manufacturer's instruction. PCR was performed on library DNA for 12--17 cycles after which all libraries were pooled according to Illumina HiSeq specifications. Sequencing was sent to Illumina and carried out according to the following specifications: 50-nt single-end run, dedicated index sequencing. Dedicated 6-mer indexes were used to demultiplex the libraries of different samples. All libraries used in this study are listed and described in [Supplementary file 2](#supp2){ref-type="supplementary-material"}.

Antibody validation {#s4-10}
-------------------

### Immunofluorescence staining {#s4-10-1}

Adult worms were washed in 1X PBS twice and paralyzed in 0.1 mM levamisole in 1X PBS. Paralyzed worms were transferred to a cavity slide and gonads were dissected using two 25-gauge syringe needles. The dissected gonads were first fixed in 100% methanol in 1X PBS at −20°C for 1 min, and then were fixed in 2% paraformaldehyde in 1X PBS at room temperature for 5 min. After fixation, gonads were blocked in blocking buffer (1 mg/ml BSA, 10% Normal Goat Serum, 0.1% Tween 20, 1X PBS) for 45 min at room temperature. For primary antibody staining, gonads were incubated in Rabbit-anti-H3K23me3 (1:150, Active Motif, 61499) in blocking buffer at 4°C overnight. For antibody competition, primary antibody was pre-absorbed with 25 ng/µL corresponding histone proteins or histone peptide at room temperature for 1 hr, and was centrifuged at 14,000 rpm at 4°C for 10 min to remove immune complexes. The histone proteins and peptide used for antibody competition were histone H3K23me3 (Active motif, 31264), histone H3K9me3 (Active motif, 31601), unmodified histone H3 (Abcam ab2903), H3K27me3 histone peptide (Abcam ab1782). For secondary antibody staining, gonads were washed three times for 5 min each wash in 1X PBS/0.1% Tween 20, and then were incubated in Donkey Anti-Rabbit-Alexa Fluor 488 (1:300, Jackson ImmunoResearch Laboratories, 711-545-152) in blocking buffer at room temperature for 2 hr. The gonads were then washed three times for 5 min each wash in 1X PBS with 0.1% Tween 20. 100 ng/ml DAPI was added to the last wash to stain chromosomes. Gonads were mounted in Slowfade (Invitrogen) onto a freshly made 2% agarose pad for imaging. Gonads were imaged using a Zeiss Axio Imager M2 system. Images were processed with Fiji (ImageJ) ([@bib38]).

### Western blot {#s4-10-2}

Worm grinds were lysed in 2X Laemmli buffer with 1X HALT protease and phosphatase inhibitor (Thermo Fisher Scientific) by boiling at 95°C for 5 min. Worm lysate (25 µg /lane) were loaded and separated on Bio-Rad TGX Any KD gel and transferred to nitrocellulose membrane. Primary antibodies used are polyclonal Rabbit-anti-H3K23me1 (1:1000, Active Motif 39388), polyclonal Rabbit-anti-H3K23me2 (1:1000, Active Motif 39654), polyclonal Rabbit-anti-H3K23me3 (1:1000, Active Motif 61500), polyclonal Rabbit-anti-H3K9me3 (1:1000, Abcam ab8898), monoclonal Mouse-anti-tubulin (1:250, DSHB AA4.3). Secondary antibodies used are Cy5-conjugated donkey anti-Rabbit IgG secondary antibody (1:1000, Jackson ImmunoResearch Laboratories 711-175-152) and Cy5-conjugated donkey anti-Mouse IgG secondary antibody (1:1000, Jackson ImmunoResearch Laboratories, 715-175-150). Fluorometric detection and measurement was preformed using GE/Amersham Typhoon RGB scanner and ImageQuant software (GE Healthcare).

High-throughput sequencing {#s4-11}
--------------------------

Pooled libraries were sequenced on an Illumina HiSeq 2500 platform (rapid run mode, 50-nt single-end run, and index sequencing). De-multiplexed raw data in fastq format were provided by the sequencing service facility. Library information is listed in [Supplementary file 2](#supp2){ref-type="supplementary-material"}. High-throughput sequencing data generated for this study have been deposited in NCBI Gene Expression Omnibus (accession number GSE141347).

Data analysis {#s4-12}
-------------

Fastq files of each library were aligned directly to *C. elegans* genome (WS190 version) using the Bowtie alignment program (version 1.2.2), only perfect alignments were reported and used ([@bib20]). When a read aligned to multiple loci the alignment was counted as 1/(number alignments). For all data analysis, normalization was based on the sequencing depth of each library (total number of reads aligned). For some figures, normalization was additionally based on the respective input library (no antibody), where this is done it is stated in the figure legend. For individual loci coverage, each read was extended by 500 bp from the sequenced end. Whole chromosome coverage analysis was done based on 1 kb windows for the entire genome. All coverage plot figures were created using custom python scripts and custom R scripts in ggplot2.

We and others have characterized over 150 genomic loci in *C. elegans* that are de-silenced and/or lose repressive chromatin modifications in nuclear RNAi-deficient mutants, the so-called 'endogenous targets'. These endogenous targets are also referred to as GRH and GRTS loci. GRH regions are defined as regions with germline nuclear RNAi dependence. GRTS regions are defined at regions with germline nuclear-RNAi-dependent transcriptional silencing. ([@bib30]; [@bib31]; [@bib17]).

ChIP-seq replicates {#s4-13}
-------------------

Plots of ChIP-seq data are representative of either one, two or three replicates as follows:

ChIPGenotypeRNAiNumber of replicatesH3K23me3N2*oma-1*2H3K23me3*hrde-1oma-1*1H3K23me3*set-32oma-1*2H3K23me3*met-2 set-25oma-1*2H3K23me3N2none3H3K23me3*hrde-1*none3H3K23me3*set-32*none3H3K23me3*met-2 set-25*none3H3K23me3*glp-1*none1

Library information can be found in [Supplementary file 2](#supp2){ref-type="supplementary-material"}.

Venn diagram analysis {#s4-14}
---------------------

We used venn.js (<https://github.com/benfred/venn.js/>), a library in D3.js. To layout each Venn diagram proportional to the input sizes, we defined the sets, and specified the size of each individual set as well as the size of all set intersections. The sizes of all sets and intersections were found in custom R scripts. Each set was defined using two replicate libraries.

Repeat analysis {#s4-15}
---------------

Repeat masker data were downloaded from UCSC table browser, with repeat class specified for each repeat. The *hrde-1-*dependent H3K23me3/H3K9me3 genes were found by comparing N2 with *hrde-1* mutant (two fold cutoff and p-value\<0.05). Two replicas of *hrde-1* mutant were used and only genes that were identified in both replicas were then used for subsequent repeat analysis. Data were then saved in bed format, with chromosome start and end position for each gene or repeat.

The Bioconductor package 'ChIPpeakAnno' was used for overlapping repeats with genes (Chapter 4.1 in ChIPpeakAnno user\'s guide: <https://www.bioconductor.org/packages/devel/bioc/vignettes/ChIPpeakAnno/inst/doc/ChIPpeakAnno.html>). We used findOverlapsOfPeak (bed1, bed2) command to overlap the target genes with repeat masker tracks. The output 'peaklist' object included information regarding genes that did not overlap with any repeats. Pie charts were made to represent the number of genes that did or did not contain repeats identified by Repeat Masker. For the genes that did contain repeats we used pie charts to display what kinds of repeat classes were present in the set.
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###### Top *set-32* and *hrde-1* dependent genes.

A list of top *set-32*-dependent H3K23me3 genes taken from annotated list of 20911 *C. elegans* genes. In the second list, the top *hrde-1*-dependent H3K23me3 genes. The top genes were defined as those that were threefold higher in WT versus mutant in two libraries with a p-value of \<0.05.

###### List of experiments, libraries, sequencing depth used in this study.

ChIP-seq libraries are listed by experiment.

###### Oligonucleotides and other sequences used in this study.

Data availability {#s7}
=================

Sequencing data have been deposited in GEO under accession codes GSE141347 Mass spec raw files generated with mass spectrometry are freely accessible at <https://chorusproject.org/>, project number 1636 (access to the data requires creating a free account).

The following datasets were generated:

Schwartz-OrbachLNiJGuS2019C. elegans nuclear RNAi factor SET-32 is an H3K23 methyltransferase and deposits the transgenerational heritable modification of H3K23me3NCBI Gene Expression OmnibusGSE141347

SidoliSGuS2019C. elegans nuclear RNAi factor SET-32 is an H3K23 methyltransferase and deposits the transgenerational heritable modification of H3K23me3Chorus1636

10.7554/eLife.54309.sa1

Decision letter

Akhtar

Asifa

Reviewing Editor

Max Planck Institute for Immunobiology and Epigenetics

Germany

Rechavi

Oded

Reviewer

Tel Aviv University

Israel

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your article \"*C. elegans* nuclear RNAi factor SET-32 deposits the transgenerational heritable histone modification, H3K23me3\" for consideration by *eLife*. Your article has been reviewed by Kevin Struhl as the Senior Editor, a Reviewing Editor, and three reviewers.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The three reviewers are interested in your manuscript and actively discussed that more functional analysis in needed to further substantiate the study regarding the role of H3K23me3 in regulation of gene expression. Furthermore, it was discussed that case inheritance of H3k23me3 is not convincing. It remains possible that small RNAs are inherited and the H3K23me3 in future generations could be a consequence. We therefore encourage you to submit a revised version of the manuscript providing more mechanistic insights in the role of small RNAs in the inheritance of H3K23me3.

Essential revisions:

In particular, we would like you to provide experimental evidence whether the H3K23me3 is inherited meiotically or re-established at each generation with the help of small RNAs. This could be done, for example by employing HRDE-1 mutants. Also, the physiological role of the H3K23me3 remains unclear. This could be address for example by performing qPCR experiments at the *oma-1* locus after 4 generations. More generally, the phenotype of the embryo lacking SET-32 should be analyzed and discussed.

The individual reviews are attached below to so that you can see the specific concerns raised by each reviewer.

Reviewer \#1:

I enjoyed this very interesting paper by Schwartz-Orbach et al. It continues their past work on the involvement of HMTs and other chromatin marks (mostly K9) in silencing and transgenerational RNAi in *C. elegans*. K9 methylations, while originally thought to be crucial for heritable RNAi, are now known to be important only in specific cases (for heritable regulation of specific genes, mostly newly evolved genes, and K9 mutants are largely ok. Chromatin marks, like K9me1/2/3 do play a role in transgenerational RNAi, modulating it and controlling its duration, and this likely involves also interactions with other histone modifications. The discovery presented here, that H3K23me3 (an abundant mark) plays a role in nuclear RNAi, could shed light on the mechanism. The authors provide evidence that their antibody is specific, and that loci which are targeted by endogenous and exogenous small RNAs indeed get modified with the mark. Also, the involvement of SET-32 and HRDE-1 (both play a role but are not completely required) is convincing. I think these are all valuable discoveries that would be interesting to many in the field.

Reviewer \#2:

In the paper \"*C. elegans* nuclear RNAi factor SET-32 deposits the transgenerational heritable histone modification, H3K23me3\" the authors use *C. elegans* as a model system to study the H3K23me3 epigenetic mark in the germline.

The current work in *eLife* from Sam Gu lab is really timing and potentially could increase our understanding of H3K23me3, its role in the transgenerational inheritance of repressive epigenetic states and its role in the phenomenon of RNAi. Although the paper is very sound, there are some major points below that need to be addressed and that are required to strengthen the paper for a publication in *eLife*.

From their study, it is clear that SET-32 methylation activity is toward H3K23 and that the appearance of H3K23me3 relies upon exogenous dsRNA. Despite the authors show in Figure 2B that the levels of H3K23me3 seems higher than H3K9me3 (after 4 generations), I believe this is not very convincing and I would rather interpret from their plot that H3K23me3 behave very similarly to H3K9me3 (upon normalisation). This data should be validated by qChIP, just on this locus.

The authors should also tag SET-32 so that to perform ChIP-seq and also IP from whole embryo with subsequent mass spec, trying to identify the protein complex containing SET-32.

The paper also lacks some more functional studies. The authors should deplete/ or make a catalytic dead of SET-32 and study the phenotype of the worms. Moreover, in this mutant background the authors should study the transcriptional effect/defect on exogenous and endogenous RNAi depended sites.

Reviewer \#3:

This is quite an interesting study that characterises SET-32 as an H3K23me3 histone methyl transferase and links this under-studied histone modification to the nuclear RNAi pathway and heterochromatin in *C. elegans*.

What is missing is any convincing insight into the role of H3K23me3 in the nuclear RNAi pathway or gene repression. Therefore, the speculations in the discussion trying to link published SET-32 phenotypes to the role of H3K23me3 in the establishment or maintenance of nuclear RNAi mediated silencing are very vague. Otherwise the overall quality of the study seems to be good.

Sometimes the statements in the text do not reflect the data (e.g. ChIP data profiles subsection "*set-32* and *hrde-1* are required for nuclear RNAi-induced H3K23me3". vs Figure 4---figure supplement 1).

Essential revisions:

It is hard to untangle the SET-32 H3K23 and H3K9 HMT activity -- one possibility would be to create mutants that lack one or the other HMT activity. Also, site-specific (e.g. *oma-1* locus) demethylation of H3K9me3 by Cas9-based epigenome editing. Both approaches are however probably out of scope for this study. *set-32* mutants still show H3K23me3 marks, which speaks for the presence of additional and unknown H3K23me3 HMT(s), making functional insights even more challenging to obtain. RNA expression data to accompany the multigenerational ChIP profiles at the *oma-1* locus (Figure 2B). This would reveal whether there is still a significant repression at the F4 generation when H3K9me seems to be reduced to background levels, but H3K23me3 still shows a (small) peak.

Figure 4B does not appear to be a very representative locus to show given the genome-wide data but rather one that matches the prior hypothesis.

The exact definitions of GRH and GRTS genes need to be given in the methods.

Subsection "H3K23me3 is a heterochromatic mark in *C. elegans"*. referring to Figure 3A: there is similarity between H3K9me3 and H3K23me3; however, such similarity is not present between H3K9me3 and H3K23me2 as stated by the author. Similarity on different chromosomes (Figure 3---figure supplement 1) also shows a very weak correlation between H3K9me3 and H3K23me3 at Chr III.

Subsection "H3K23me3 is a heterochromatic mark in *C. elegans"* states that H3K23me1 is uniformly distributed (Figure 3---figure supplement 1) but it looks like H3K23me2 distribution across the genome is just as uniform and doesn\'t cluster at the constitutive heterochromatic regions as H3K23me3 or H3K9me3.

These results and distributions all need quantifying.

Results section: There is no reference to Figure 4B in the text (endogenous *hrde-1* target).

Results section: Figure 4 should be renamed Figure 4C-G as these represent the genome-wide data mentioned in the sentence.

Results section: Figure 4---figure supplement 1 shows slightly stronger H3K9me3 reduction in regions of germline nuclear RNAi-mediated heterochromatin (GRH). However, regions of germline nuclear RNAi-mediated transcriptional silencing (GRTS) show even a stronger depletion of H3K9me3 in *set-32* mutants compared to *met-2 set-25* double mutants. This is not in line with the statement of the author \"As in published works, we found that H3K9me3 has a larger requirement of MET-2 and SET-25 than SET-32\" and the conclusion that this further supports different functions of SET-32 and MET-2/SET-25.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for submitting your article \"*C. elegans* nuclear RNAi factor SET-32 deposits the transgenerational heritable histone modification, H3K23me3\" for consideration by *eLife*. Your article has been reviewed by Kevin Struhl as the Senior Editor, a Reviewing Editor, and three reviewers. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.

Reviewers are overall supportive and also sympathetic about the circumstances based on which some of the additional key experiments could not be performed. However, since you have not addressed the most significant concerns of the reviewers, namely that the multi-generation \'inheritance\' of H3K23me3 may be a secondary consequence of the transmission of small RNAs or other histone modifications and the lack of \'function\' for H3K23me3. The title and associated text need to be toned down.

Furthermore, please explicitly state (Figure legend and text) where experiments are performed without biological replicates and tone down the strength of the conclusions. For example, as pointed out by reviewer\#2: \"These findings indicate that the regulation of H3K23me3 at nuclear RNAi targets is complex, and likely to involve other HMTs\", as this cannot be concluded based on experiments lacking biological replicates and therefore not being quantitative.

Reviewer \#1:

I didn\'t have too many issues with the original submission and the few questions that I had have been answered in the revision process. The authors wrote that their attempts to examine the role of HRDE-1 were disrupted due to COVID-19, that\'s reasonable.

Reviewer \#2:

The authors have addressed some major concerns and the paper could be accepted for publication.

I, though, noticed that many ChIP experiments do not have biological replicates.

This is especially relevant for the second paragraph of subsection "*set-32* and *hrde-1* are required for nuclear RNAi-induced H3K23me3"; where the authors try to understand the loss of H3K23me3 in different mutant backgrounds.

I suggest to remove from this paragraph the sentence \" These findings indicate that the regulation of H3K23me3 at nuclear RNAi targets is complex, and likely to involve other HMTs.\", as this cannot be concluded based on experiments lacking biological replicates and therefore not being quantitative.

The authors should also mention in the figure legends the number of biological replicates for each experiment, each time, as otherwise for the reader it is hard to find this info.

Reviewer \#3:

Unfortunately the authors have not been able to definitively address the most important referee concerns -- that the multi-generation \'inheritance\' of H3K23me3 may be a secondary consequence of the transmission of small RNAs or other histone modifications and the lack of \'function\' for H3K23me3. However, I do think this is an interesting body of work.

For the reasons stated in the original reviews, I think the title has the potential to be misleading to a general audience: \'transgenerational heritable histone modification\' is a strong statement and something that has not been directly demonstrated and I think this should be toned down.

10.7554/eLife.54309.sa2

Author response

> Essential revisions:
>
> In particular, we would like you to provide experimental evidence whether the H3K23me3 is inherited meiotically or re-established at each generation with the help of small RNAs. This could be done, for example by employing HRDE-1 mutants.

We agree that this is an important question in the field of nuclear RNAi. We have been developing auxin-inducible degradation (AID) of HRDE-1 to address this question. To prepare for the revision, we constructed and performed some initial characterization of the AID system, which had produced promising preliminary results. Unfortunately, the experiments were interrupted by the pandemic lockdown. Given the uncertainty of the situation and the scope of the project, we feel that the HRDE-1 AID experiments are more suitable for a future paper.

> Also, the physiological role of the H3K23me3 remains unclear.

Our study indicated that SET-32 is not the only writer for H3K23me. Understanding the physiological role of H3K23me3 requires the identification of the other writers, as well potential H3K23me readers, which is beyond the scope of this study. As suggested by reviewer \#2, characterizing a catalytic inactive SET-32 mutant may provide connection between H3K23me3 and the phenotype of the *set-32*(-) (e.g. silencing establishment defect). This turned out to be more challenging than expected as all of our five attempts of creating the mutant failed.

> This could be address for example by performing qPCR experiments at the oma locus after 4 generations.

It is well established that heritable RNAi of *oma-1* can persist for at most 4-5 generations in WT animals (e.g. PMIDs:18757930, 28343968, 32348780). We and others have shown that SET-32 promotes silencing establishment, presumably through H3K23me3, but is dispensable for heritable silencing at *oma-1*(PMIDs:30463020 and 30463021). The function of H3K23me3 (and also H3K9me3) in the heritable generations is unclear at this point.

> More generally, the phenotype of the embryo lacking SET-32 should be analyzed and discussed.

We performed brood size analysis and found that *set-32*(-) animals have similar brood sizes as WT animals at both 20ºC (WT:303, *set-32*(-):307) and 25ºC (WT:203, *set-32*(-):219). In addition, a published work (PMID 30463020) did not observe any developmental defects in *set-32*(-) animals, including embryogenesis, we have included these points in the revised manuscript (Discussion section).

> Reviewer \#2:
>
> \[...\] Although the paper is very sound, there are some major points below that need to be addressed and that are required to strengthen the paper for a publication in eLife.
>
> From their study, it is clear that SET-32 methylation activity is toward H3K23 and that the appearance of H3K23me3 relies upon exogenous dsRNA. Despite the authors show in Figure 2B that the levels of H3K23me3 seems higher than H3K9me3 (after 4 generations), I believe this is not very convincing and I would rather interpret from their plot that H3K23me3 behave very similarly to H3K9me3 (upon normalisation). This data should be validated by qChIP, just on this locus.

We agree that comparison of the relative enrichment of different histone marks, needs to be careful. Both H3K23me3 and H3K9me3 at the F4 are much lower than the P0 levels. In the revised manuscript, we removed the description regarding the comparison of H3K9me3 and H3K23me3 levels at the F4 generation and put H3K9me3 and H3K23me3 in different panels (2C and 2D) to avoid confusion.

> The authors should also tag SET-32 so that to perform ChIP-seq and also IP from whole embryo with subsequent mass spec, trying to identify the protein complex containing SET-32.

We have performed size exclusion chromatography analysis of SET-32 from the crude worm lysate. All the detectable SET-32 behaved as a monomer in this analysis (data not shown). The result suggests that either (1) SET-32 functions as a monomer, (2) the interaction between SET-32 and its binding partner is weak, or (3) only a very small fraction of SET-32 function as a complex. Distinguishing these possibilities are beyond the scope of this paper.

> The paper also lacks some more functional studies. The authors should deplete/ or make a catalytic dead of SET-32 and study the phenotype of the worms. Moreover, in this mutant background the authors should study the transcriptional effect/defect on exogenous and endogenous RNAi depended sites.

As mentioned above, we agree with the importance of studying catalytic dead *set-32* mutant. However, we were not able to obtain the mutation after trying five different CRISPR designs.

> Reviewer \#3:
>
> \[...\]
>
> What is missing is any convincing insight into the role of H3K23me3 in the nuclear RNAi pathway or gene repression. Therefore, the speculations in the discussion trying to link published SET-32 phenotypes to the role of H3K23me3 in the establishment or maintenance of nuclear RNAi mediated silencing are very vague.

We agree that functional insight is lacking, as mentioned above, our study indicated that SET-32 is not the only writer for H3K23me. Understanding the role of H3K23me3 requires the identification of the other writers, as well potential H3K23me readers, which is beyond the scope of this study.

> Otherwise the overall quality of the study seems to be good.
>
> Sometimes the statements in the text do not reflect the data (e.g. ChIP data profiles subsection "set-32 and hrde-1 are required for nuclear RNAi-induced H3K23me3" vs Figure 4---figure supplement 1).

We have updated the text in several places to better reflect the data. Thank you for alerting us to these oversights.

> Essential revisions:
>
> It is hard to untangle the SET-32 H3K23 and H3K9 HMT activity -- one possibility would be to create mutants that lack one or the other HMT activity. Also, site-specific (e.g. oma-1 locus) demethylation of H3K9me3 by Cas9-based epigenome editing. Both approaches are however probably out of scope for this study.

We agree that both questions are highly interestingly. In our *in vitro* biochemical analysis, the recombinant SET-32 only has H3K23 HMT activity and does not methylate any other lysines in H3. The amino acid sequence flanking K9 and K23 are distinct, therefore, it's unlikely that SET-32 can also methylate H3K9 *in vivo* although this has not been formally ruled out. Future study is required to untangle the functional relationship between H3K9me3 and H3K23me3. We have included these points in the Discussion section of the revised manuscript.

Site-specific demethylation of H3K9me3 or H3K23me3 by Cas9-based epigenome editing is a very interesting idea. We are not aware of this approach having been successfully used in *C. elegans*. We agree that building such a tool is indeed out of scope for this study.

> set-32 mutants still show H3K23me3 marks, which speaks for the presence of additional and unknown H3K23me3 HMT(s), making functional insights even more challenging to obtain. RNA expression data to accompany the multigenerational ChIP profiles at the oma-1 locus (Figure 2B). This would reveal whether there is still a significant repression at the F4 generation when H3K9me seems to be reduced to background levels, but H3K23me3 still shows a (small) peak.

We responded to this issue above.

In addition, as suggested by reviewer \#2, it is difficult to compare relative enrichment of two different histone marks. Both H3K9me3 and H3K23me3 at the F4 were much weaker than the P0 levels. We have removed the description regarding the comparison between H3K9me3 and H3K23me3 at F4.

> Figure 4B does not appear to be a very representative locus to show given the genome-wide data but rather one that matches the prior hypothesis.

We have added three more loci to Figure 4 to better represent the data. In addition, there are four other loci plotted in Figure 4---figure supplement 1. We have updated the text to further explain the differences in reduction of the same mutants at different loci. We expanded the descriptions of these findings to make it clearer.

> The exact definitions of GRH and GRTS genes need to be given in the methods.

We have added this in the revised manuscript.

> Subsection "H3K23me3 is a heterochromatic mark in C. elegans". referring to Figure 3A: there is similarity between H3K9me3 and H3K23me3; however, such similarity is not present between H3K9me3 and H3K23me2 as stated by the author. Similarity on different chromosomes (Figure 3---figure supplement 1) also shows a very weak correlation between H3K9me3 and H3K23me3 at Chr III.
>
> Subsection "H3K23me3 is a heterochromatic mark in C. elegans" states that H3K23me1 is uniformly distributed (Figure 3---figure supplement 1) but it looks like H3K23me2 distribution across the genome is just as uniform and doesn\'t cluster at the constitutive heterochromatic regions as H3K23me3 or H3K9me3.
>
> These results and distributions all need quantifying.

In order to better address this point and make a clearer understanding we performed box plot analysis of the chromosome coverage and split each chromosome into three sections: the heterochromatic arms and the euchromatic center (Figure 4---figure supplement 2). We compared these regions for each modification in order to better assess the distribution of the marks. In this analysis, we found that your observations were correct: H3K23me2 has a much more uniform distribution than H3K9me3. This analysis also showed that there is a much weaker correlation between H3K23me3 and H3K9me3 chromosome three. By presenting this data in the updated manuscript, readers will get a more accurate view of the modifications' distributions.

> Results section: There is no reference to Figure 4B in the text (endogenous hrde-1 target).

This has been amended.

> Results section: Figure 4 should be renamed Figure 4C-G as these represent the genome-wide data mentioned in the sentence.

This has been amended.

> Results section: Figure 4---figure supplement 1 shows slightly stronger H3K9me3 reduction in regions of germline nuclear RNAi-mediated heterochromatin (GRH). However, regions of germline nuclear RNAi-mediated transcriptional silencing (GRTS) show even a stronger depletion of H3K9me3 in set-32 mutants compared to met-2 set-25 double mutants. This is not in line with the statement of the author \"As in published works, we found that H3K9me3 has a larger requirement of MET-2 and SET-25 than SET-32\" and the conclusion that this further supports different functions of SET-32 and MET-2/SET-25.

We apologize for the confusion. Upon revisiting our published works, we realized that most of the data presented in the original Figure S7 is available in (PMID: PMC5311726, Figure S3), these data have been removed from the manuscript. In the whole genome there are more *met-2 set-25*-dependent H3K9me3 loci than *set-32*-dependent H3K9me3 loci.

However, we see a similar dependence on *set-32* and *met-2 set-25* in the GRTS and GRH regions. There is more H3K9me3 loss (in GRH regions) in *set-32* than *met-2 set-25*, but we think such small difference is not biologically significant. We observed that *set-32* mutant has H3K9me3 defect and *met-2 set-25* mutant has H3K23me3 defect. The functional significance of the crosstalk is unknown and requires future investigation. We have updated the text to reflect these findings.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

> Reviewer \#2:
>
> The authors have addressed some major concerns and the paper could be accepted for publication.
>
> I, though, noticed that many ChIP experiments do not have biological replicates.
>
> This is especially relevant the second paragraph of subsection "set-32 and hrde-1 are required for nuclear RNAi-induced H3K23me3"; where the authors try to understand the loss of H3K23me3 in different mutant backgrounds.
>
> I suggest to remove from this paragraph the sentence \" These findings indicate that the regulation of H3K23me3 at nuclear RNAi targets is complex, and likely to involve other HMTs.\", as this cannot be concluded based on experiments lacking biological replicates and therefore not being quantitative. The authors should also mention in the figure legends the number of biological replicates for each experiment, each time, as otherwise for the reader it is hard to find this info.

We have addressed this concern in both the Materials and methods section, supplementary files and figure legends. For example, we made a new subsection "ChIP-seq replicates" listing the number of replicates for each experiment. For most experiments there are at least two biological replicates. For *oma-1* heritable RNAi there is only 1 replicate and for H3K23me2 and H3K23me1 there is only one replicate for each experiment. All the rest have two to three replicates.

> Reviewer \#3:
>
> Unfortunately the authors have not been able to definitively address the most important referee concerns -- that the multi-generation \'inheritance\' of H3K23me3 may be a secondary consequence of the transmission of small RNAs or other histone modifications and the lack of \'function\' for H3K23me3. However, I do think this is an interesting body of work.
>
> For the reasons stated in the original reviews, I think the title has the potential to be misleading to a general audience: \'transgenerational heritable histone modification\' is a strong statement and something that has not been directly demonstrated and I think this should be toned down.

We agree that at this point we do not know the mechanism by which dsRNA-induced H3K23me3 persists in the later generations. We have changed our language to reflect this. We no longer use the phrase "transgenerationally inherited". In the revised manuscript, we replaced it with either "transgenerational epigenetic effect" or "transgenerational histone modification".
